✦ LIBER ✦

Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

✍ Scribed by Ricardo Hitt; Maria L. Amador; Miguel Quintela-Fandino; Antonio Jimeno; Olga del Val; Susana Hernando; Hernan Cortes-Funes

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 107 KB
Volume: 106
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.21579

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of paclitaxel, ifosfamide

Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma

✍ Dong M. Shin; Fadlo R. Khuri; Bonnie S. Glisson; Lawrence Ginsberg; Vali M. Papa 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 2 views

Vinblastine, bleomycin and cisplatin for

Vinblastine, bleomycin and cisplatin for recurrent or metastatic squamous cell carcinoma of the head and neck

✍ David J. Perry; Martin D. Weltz; Archie W. Brown Jr; Robert L. Henderson; Willia 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 315 KB 👁 2 views

Forty-two patients with recurrent or metastatic squamous cell carcinoma of the head and neck were treated with vinblastine, bleomycin, and cisplatin. All patients had received prior surgery, radiation or chemotherapy and all had measurable disease. Forty-five percent of the patients responded with a

A phase II trial of cisplatin and vinore

A phase II trial of cisplatin and vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

✍ Enrique Espinosa; Pilar Zamora; Alfredo Millá; Serafin Morales; Raquel Molina; M 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB 👁 1 views

## Abstract ## Objective. We assessed the response rate and the toxicity of cisplatin plus vinorelbine in patients with this condition. ## Patients and Method. Forty‐two patients were included. Therapy consisted of cisplatin, 100 mg/m^2^ on day 1, and vinorelbine, 25 mg/m^2^ on days 1 and 8, giv

Phase II trial of irinotecan plus cispla

Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck

✍ Jill Gilbert; Anthony Cmelak; Yu Shyr; James Netterville; Brian B. Burkey; Rober 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 1 views

Survival in patients with recurrent squa

Survival in patients with recurrent squamous cell head and neck carcinoma treated with bio-chemotherapy

✍ Mario Airoldi; Antonella De Stefani; Sara Marchionatti; Fulvia Pedani; Pietro Ga 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 1 views

## Abstract ## Background We have shown that rIL‐2 administration in recurrent head and neck cancers induces a tumor‐specific T‐lymphocyte reactivity and tumor regression; in a pilot study we have shown a safe and effective administration of rIL2 after cisplatin + 5‐fluorouracil. Long‐term results

Efficacy of neck treatment in patients w

Efficacy of neck treatment in patients with head and neck squamous cell carcinoma

✍ Gabriela Buck; Pia Huguenin; Sandro J. Stoeckli 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 1 views

## Abstract ## Background. Treatment of head and neck squamous cell carcinoma (HNSCC) addresses the primary tumor and the lymphatic drainage. Modalities for the neck are neck dissection and/or radiation therapy. In most cases, the neck is treated by the modality that seems more appropriate for the